Neuropsychiatric Symptoms of Epilepsy

5 Delusions and Hallucinations
89
92. Adachi N. Epilepsy as a risk factor for schizophrenia. Presented in the 13th Pacific Rim
College of Psychiatrists Scientific Meeting. Tokyo, 2008.
93. Ingram RE, Price JM. The role of vulnerability in understanding psychopathology. In: Ingram
RE, Price JM, editors. Vulnerability to psychopathology. Risk across the lifespan. New York:
Guilford press; 2001. p. 3–19.
94. Koutroumanidis M, Adachi N, Howard R. History, physical and mental examination, and assessment.
In: Panayiotopoulos CP, editor. Atlas of epilepsies. London: Springer; 2010. p. 671–80.
95. Onuma T. Therapeutic approach to epileptic patients with psychiatric symptoms. Jpn J
Psychiatry Treat. 1987;2:553–60 [Japanese].
96. Adachi N. Treatment of mental disorders in epilepsy patients. Jpn J Psychiatry Treat.
2005;20(Suppl):370–3 [Japanese].
97. Adachi N, Kanemoto K, de Toffel B, Akanuma N, Oshima T, Mohan A, et al. Basic treatment
principles for psychotic disorders in patients with epilepsy. Epilepsia. 2013;54 Suppl 1:19–33.
98. Kerr M, Mensah S, Besag F, de Toffol B, Ettinger A, Kanemoto K, et al. International consensus
clinical practice statements for the treatment of neuropsychiatric conditions associated
with epilepsy. Epilepsia. 2011;52:2133–8.
99. American Psychiatric Association. Practice guideline for the treatment of patients with
schizophrenia. Am J Psychiatry. 1998;154 Suppl 4:1–63.
100. Krauss G, Theodore WH. Treatment strategies in the postictal state. Epilepsy Behav.
2010;19:188–90.
101. Lancman ME, Craven WJ, Asconapé JJ, Penry JK. Clinical management of recurrent postictal
psychosis. J Epilepsy. 1994;7:47–51.
102. Adachi N, Akanuma N, Ito M, Okazaki M, Kato M, Onuma T. Interictal psychotic episodes
in epilepsy: duration and associated clinical factors. Epilepsia. 2012;53:1088–94.
103. Francey SM, Nelson B, Thompson A, Parker AG, Kerr M, Macneil C, et al. Who need antipsychotic
medication in the earliest stage of psychosis? A reconsideration of benefits, risks,
neurobiology and ethics in the era of early intervention. Schizophr Res. 2010;119:1–10.
104. Crossley NA, Constante M, McGuire P, Power P. Efficacy of atypical v. typical antipsychotics
in the treatment of early psychosis: meta-analysis. Br J Psychiatry. 2010;196:434–9.
105. Girgis RR, Phillips MR, Li X, Li K, Jiang H, Wu C, et al. Clozapine v. chlorpromazine in
treatment-naïve, first-episode schizophrenia: 9-year outcomes of a randomized clinical trial.
Br J Psychiatry. 2011;199:281–8.
106. Hara K, Adachi N, Okazaki M, Ito M, Akanuma N, Kato M, et al. Duration of interictal psychotic
episodes by antipsychotic drug treatments. Epilepsy Behav. 2013;27:342–5.
107. Okazaki M, Adachi N, Akanuma N, Hara K, Ito M, Kato M, Onuma T. Do antipsychotic
drugs increase seizure frequency in epilepsy patients? Eur Psychoneuropharmachol.
2014;24:1738–44.
108. Gardner DM, Murphy AL, O’Donnel H, Centorrino F, Baldessarini RJ. International consensus
study of antipsychotic dosing. Am J Psychiatry. 2010;167:686–93.
109. Cockerell OC, Walker MC, Sander JWAS, Shorvon SD. Complex partial status epilepticus: a
recurrent problem. J Neurol Neurosurge Psychiatry. 1994;57:835–7.
110. Devinsky O, Abramson H, Alper K, FitzGerald LS, Perrine K, Calderon J, Luciano
D. Postictal psychosis: a case control series of 20 patients and 150 controls. Epilepsy Res.
1995;20:247–53.
111. Kanner AM, Ostrovskaya A. Long-term significance of postictal psychotic episodes II. Are
they predictive of interictal psychotic episodes? Epilepsy Behav. 2008;12:154–6.
112. Onuma T, Adachi N, Hisano T, Uesugi S. 10-year follow-up study of epilepsy with psychosis.
Jpn J Psychiat Neurol. 1991;45:360–1.
113. Harris EC, Barraclough B. Excess mortality of mental disorder. Br J Psychiatry.
1999;173:11–53.
114. Hitiris N, Mohanraj R, Norrie J, Brodie MJ. Mortality in epilepsy. Epilepsy Behav.
2007;10:363–76.